These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 32125179)

  • 1. Synthesis and evaluation of potent human immunodeficiency virus 1 protease inhibitors with epimeric isopropanol as novel P1' ligands.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Future Med Chem; 2020 May; 12(9):775-794. PubMed ID: 32125179
    [No Abstract]   [Full Text] [Related]  

  • 2. Design and biological evaluation of novel HIV-1 protease inhibitors with isopropanol as P1' ligand to enhance binding with S1' subsite.
    Zhu M; Ma L; Dong B; Zhang G; Wang J; Zhou J; Cen S; Wang Y
    Bioorg Med Chem; 2020 Aug; 28(16):115623. PubMed ID: 32690263
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance.
    Ghosh AK; Chapsal BD; Weber IT; Mitsuya H
    Acc Chem Res; 2008 Jan; 41(1):78-86. PubMed ID: 17722874
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Protease Inhibitors Incorporating Stereochemically Defined P2' Ligands To Optimize Hydrogen Bonding in the Substrate Envelope.
    Rusere LN; Lockbaum GJ; Lee SK; Henes M; Kosovrasti K; Spielvogel E; Nalivaika EA; Swanstrom R; Yilmaz NK; Schiffer CA; Ali A
    J Med Chem; 2019 Sep; 62(17):8062-8079. PubMed ID: 31386368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, Synthesis, Biological Evaluation, and X-ray Studies of HIV-1 Protease Inhibitors with Modified P2' Ligands of Darunavir.
    Ghosh AK; Fyvie WS; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    ChemMedChem; 2017 Dec; 12(23):1942-1952. PubMed ID: 29110408
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel Protease Inhibitors Containing C-5-Modified
    Takamatsu Y; Aoki M; Bulut H; Das D; Amano M; Sheri VR; Kovari LC; Hayashi H; Delino NS; Ghosh AK; Mitsuya H
    Antimicrob Agents Chemother; 2019 Aug; 63(8):. PubMed ID: 31085520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of HIV-1 protease inhibitors with morpholine derivatives as P2 ligands in combination with cyclopropyl as P1' ligand.
    Dou Y; Zhu M; Dong B; Wang JX; Zhang GN; Zhang F; Wang YC
    Bioorg Med Chem Lett; 2020 Apr; 30(7):127019. PubMed ID: 32057582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design, synthesis, X-ray studies, and biological evaluation of novel macrocyclic HIV-1 protease inhibitors involving the P1'-P2' ligands.
    Ghosh AK; Sean Fyvie W; Brindisi M; Steffey M; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4925-4931. PubMed ID: 28958624
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and evaluation of novel piperidine HIV-1 protease inhibitors with potency against DRV-resistant variants.
    Zhu M; Zhou H; Ma L; Dong B; Zhou J; Zhang G; Wang M; Wang J; Cen S; Wang Y
    Eur J Med Chem; 2021 Aug; 220():113450. PubMed ID: 33906049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based design of novel HIV-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Sridhar PR; Leshchenko S; Hussain AK; Li J; Kovalevsky AY; Walters DE; Wedekind JE; Grum-Tokars V; Das D; Koh Y; Maeda K; Gatanaga H; Weber IT; Mitsuya H
    J Med Chem; 2006 Aug; 49(17):5252-61. PubMed ID: 16913714
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand modifications to reduce the relative resistance of multi-drug resistant HIV-1 protease.
    Dewdney TG; Wang Y; Liu Z; Sharma SK; Reiter SJ; Brunzelle JS; Kovari IA; Woster PM; Kovari LC
    Bioorg Med Chem; 2013 Dec; 21(23):7430-4. PubMed ID: 24128815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and Synthesis of Highly Potent HIV-1 Protease Inhibitors Containing Tricyclic Fused Ring Systems as Novel P2 Ligands: Structure-Activity Studies, Biological and X-ray Structural Analysis.
    Ghosh AK; R Nyalapatla P; Kovela S; Rao KV; Brindisi M; Osswald HL; Amano M; Aoki M; Agniswamy J; Wang YF; Weber IT; Mitsuya H
    J Med Chem; 2018 May; 61(10):4561-4577. PubMed ID: 29763303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design of HIV-1 Protease Inhibitors with Amino-bis-tetrahydrofuran Derivatives as P2-Ligands to Enhance Backbone-Binding Interactions: Synthesis, Biological Evaluation, and Protein-Ligand X-ray Studies.
    Ghosh AK; Martyr CD; Osswald HL; Sheri VR; Kassekert LA; Chen S; Agniswamy J; Wang YF; Hayashi H; Aoki M; Weber IT; Mitsuya H
    J Med Chem; 2015 Sep; 58(17):6994-7006. PubMed ID: 26306007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure-based design, synthesis, X-ray studies, and biological evaluation of novel HIV-1 protease inhibitors containing isophthalamide-derived P2-ligands.
    Ghosh AK; Takayama J; Kassekert LA; Ella-Menye JR; Yashchuk S; Agniswamy J; Wang YF; Aoki M; Amano M; Weber IT; Mitsuya H
    Bioorg Med Chem Lett; 2015 Nov; 25(21):4903-4909. PubMed ID: 26096678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
    Ghosh AK; Kulkarni S; Anderson DD; Hong L; Baldridge A; Wang YF; Chumanevich AA; Kovalevsky AY; Tojo Y; Amano M; Koh Y; Tang J; Weber IT; Mitsuya H
    J Med Chem; 2009 Dec; 52(23):7689-705. PubMed ID: 19746963
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design of HIV-1 protease inhibitors with pyrrolidinones and oxazolidinones as novel P1'-ligands to enhance backbone-binding interactions with protease: synthesis, biological evaluation, and protein-ligand X-ray studies.
    Ghosh AK; Leshchenko-Yashchuk S; Anderson DD; Baldridge A; Noetzel M; Miller HB; Tie Y; Wang YF; Koh Y; Weber IT; Mitsuya H
    J Med Chem; 2009 Jul; 52(13):3902-14. PubMed ID: 19473017
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure based design: novel spirocyclic ethers as nonpeptidal P2-ligands for HIV protease inhibitors.
    Ghosh AK; Krishnan K; Walters DE; Cho W; Cho H; Koo Y; Trevino J; Holland L; Buthod J
    Bioorg Med Chem Lett; 1998 Apr; 8(8):979-82. PubMed ID: 9871524
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent HIV-1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein-Ligand X-ray Structural Studies.
    Ghosh AK; Xia Z; Kovela S; Robinson WL; Johnson ME; Kneller DW; Wang YF; Aoki M; Takamatsu Y; Weber IT; Mitsuya H
    ChemMedChem; 2019 Nov; 14(21):1863-1872. PubMed ID: 31549492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.